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Abstract
Sialyl Lewis X (sLex) plays an important role in cancer metastasis. But, the mechanism for its
production in metastatic cancers remains unclear. The objective of current study was to examine
the effects of a pro-inflammatory cytokine on the expression of glycosyltransferase and
sulfotransferase genes involved in the synthesis of selectin ligands in a prostate cancer cell line.
Androgen-independent human lymph node-derived metastatic prostate cancer cells (C-81
LNCaP), which express functional androgen receptor and mimic the castration-resistant advanced
prostate cancer, was used. TNF? treatment of these cells increased their binding to P-, E- and L-
selectins, anti-sLex antibody, and anti-6-sulfo-sialyl Lewis x antibody by 12, 240, 43, 248 and
21%, respectively. Also, the expression of C2GnT-1, B4GalT1, GlcNAc6ST3, and ST3Gal3 genes
was significantly upregulated. Further treatment of TNF?-treated cells with either anti-sLex
antibody or E-selectin significantly suppressed their in vitro migration (81 and 52%, respectively)
and invasion (45 and 56%, respectively). Our data indicate that TNF? treatment enhances the
motility and invasion properties of LNCaP C-81 cells by increasing the formation of selectin
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ligands through stimulation of the expression of selective glycosyl- and sulfotransferase genes.
These results support the hypothesis that inflammation contributes to cancer metastasis.
Keywords
LNCaP cells; sLex; TNF?; glycogenes; motility and invasion
1. Introduction
Prostate cancer is the second leading cause of cancer death of men in the United States [1].
At the time of initial diagnosis, more than 70% of prostate cancer patients have lymph node
metastases [2–5]. Although metastasis is the primary cause of the fatalities of cancer
patients, the mechanism is not completely understood. One key step in the cancer metastatic
process is the adhesion of circulating cancer cells to the endothelium at distant sites. This
step involves selectin-ligand interactions between host cells (selectins) and cancer cells
(selectin ligands). Understanding how the production of these two key players is regulated
during cancer progression could help develop cancer therapeutic strategy.
Selectins are a family of type II transmembrane proteins found on the surface of leukocytes,
platelets and activated endothelial cells. They are calcium-dependent C-type lectins [6]. The
three major types of selectins include E-, P-, and L-selectins, which are located on
endothelium, platelets and activated endothelium, and leukocytes, respectively [6]. The
naturally occurring vascular carbohydrate ligands for these selectins include E-selectin
ligand-1 (ESL-1), P-selectin glycoprotein ligand-1 (PSGL-1), CD34, cutaneous lymphocyte-
associated antigen (CLA), glycoprotein GlyCAM-1, MAdCAM-1, Podocalyxin-like protein
and Sgp200 [7]. These selectin-ligand interactions were originally shown to be involved in
the trafficking of immune cells to inflamed tissues [8] and lymphoid organs, and recently in
the metastasis of cancer cells [9]. The naturally occurring vascular ligands for these selectin
molecules are mostly mucin-type glycoproteins which carry sialylated, fucosylated and
sulfated glycans [10] although some N-linked glycans also can participate in this process
[11]. Increased expression and altered glycosylation of mucins are prominent features of
carcinoma progression [10]. For example, sialyl Lewis x (sLex) and sialyl lewis a (sLea) are
increased substantially in tumors [12], including prostate cancers [13, 14]. Elevated
expression of sLex and sLea on mucin type O-glycans is highly correlated with lymphatic
and venous invasion of cancerous cells [15, 16]. SLex and 6-sulfo-sLex also were elevated
under in vivo inflammatory condition [9] and in vitro induction with proinflammatroy
cytokine, tumor necrosis factor ??(TNF?) [17, 18]. Glycosyland sulfotransferases
responsible for the biosynthesis of the above mentioned epitopes were selectively
upregulated in various cancers [19] and inflammatory conditions [9] and/or cells treated
with TNF??[17, 18]. However, a concerted effort to correlate the effects of inflammatory
cytokine on the expression of selectin ligands, glycosyl- and sulfotransferase genes
responsible for the synthesis of these ligands, interactions of these ligands with selectins,
and the acquisition of metastatic potential of the TNF?-treated cells was lacking.
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Recently, serum TNF? level was found to be increased in prostate cancer patients with
metastatic disease and elevated PSA [20]. This observation prompted us to examine whether
TNF? could enhance the metastatic potential of prostate cancer cells via stimulating the
production of sLex, an important determinant of cancer metastasis. To carry out a more
comprehensive study on the effect of TNF? on the acquisition of the sLex-related metastatic
potential in prostate cancer, we employed LNCaP C-81 cells, which exhibit properties
mimicking the clinical characteristics of advanced prostate cancers [21–23]. C-81 cells are
androgen independent, grow faster and have high colony-forming property on soft agar as
compared to LNCaP parental C-33 cells [22]. We found that treatment of the C-81 LNCaP
cells with TNF? increased the motility and invasiveness, which accompanied an increase in
selectin ligands resulted from elevated expression of selected glycosyl- and sulfotransferase
genes.
3. Materials and methods
2.1 Cell lines
The human Prostate cancer cell line LNCaP was originally purchased from the American
Type Culture Collection ATCC (Rockville, MD). The LNCaP cell model including C-33
and C-81 cells used in the present study was developed by Lin et al [22] and further
characterized by Igawa et al [21]. The cell line was maintained in RPMI 1640 medium
supplemented with 5% Fetal bovine serum, 1% L-glutamine and 1% Penicillin-
Streptomycin.
2.2 Flow Cytometry analysis of selectin interactions with ligands on LNCaP cells
Flow cytometry analysis of selectin-ligand interaction on cancer cells was carried out as
described previously [24]. Briefly, LNCaP cells of both control and TNF??(20 ng/ml, 36 h)
treated were detached from plates after incubation with PBS containing 2 mM EDTA for 5
min at 37 °C, washed three times with Hanks’ balanced salt solution (HBSS), and then
treated with 0.5% BSA in HBSS for 30 min to block nonspecific binding. Chimeras of
selectins P (50 µg/ml), E (50 µg/ml), and L (50 µg/ml) fused with Fc region of human IgG
were purified from human 293 cells (transformed embryonic kidney fibroblast cell line) of
Psel IgG, ESIg B3293 and LSRg293 Cytel, respectively [24]. These selectins were pre-
incubated with a goat-anti human IgG conjugated with FITC for 1 h at room temperature.
Similarly, sLex (KM93) (10 µg/ml) and 6-sulfo-sLex (G152) (1:10 diluted) [25] mouse
monoclonal antibodies were pre-incubated with goat anti-mouse antibody conjugated with
FITC before use. These complexes (Selectin, KM93 Ab, or G152 Ab complexed with
respective FITC-conjugated secondary antibodies) were incubated with tumor cells at 4 °C
for 2 h and then washed successively with HBSS/BSA and HBSS. Then cells were fixed
with 2 % (wt/vol) paraformaldehyde in HBSS at room temperature for 15–30 min. The cells
were then washed with HBSS and resuspended in 1 ml of HBSS/BSA for flow cytometry
analysis. Controls were cells stained in a presence of 5 mM EDTA (calcium chelation) or 30
mM EDTA in the case of P-selectin. In some instances, tumor cell surfaces were pretreated
before probing for selectin ligands. Cells treated with FITC-conjugated secondary antibody
alone served as an antibody control.
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2.3 Real Time PCR analysis of the expression of glycosyl- and sulfotransferase genes
RT-PCR analyses on LNCaP C-81 cells were performed as described previously [26]. Total
cellular RNAs were isolated from TNF? treated (20 ng/ml, 3 h) and control LNCaP cells
using the TRI-REAGENT (Molecular Research Center, Inc, USA) according to the
manufacturer protocol. cDNA was synthesized by using 2 µg of total RNA as the template in
a 20 µl RT reaction mixture by using Verso™ cDNA kit (ABgene, UK) according to the
manufacturer instruction. Quantitative real time PCR was performed on a Master cycler ep
realplex2 (Eppendorf AG, Hamburg) using SYBR Green PCR kit (Takara Bio Inc, USA).
The forward and reverse primers used for amplification of selective glycosyl- and
sulfotransferase genes are listed in Table 1. The data were analyzed using Eppendorf
realplex software, version 1.5 (Eppendorf). The amounts of various glycogene transcripts
were normalized to the amount of GAPDH transcript in same cDNA sample and expressed
as % of GAPDH. Relative fold differences in transcript expression were determined using
the following comparative CT method: 2−[Ct(TNF?)- Ct(Control)]=2− Ct, where
Ct=Ct(Target)-Ct(GAPDH) as described previously [26]. The results were expressed as the
amount (%) relative to that (100 %) of GAPDH and plotted as mean fold changes ± SEM.
2.4 Motility and Invasion assays
Motility and invasion assays were performed as previously described [23]. For motility
assays, 5×104 cells/ml of control, TNF? treated (20 ng/ml, 36 h), and TNF? treated cells
further incubated with sLex monoclonal antibody KM93 (10 µg/ml) or E-selectin (100
µg/ml) were placed on the top chamber of non-coated polyethylene terapthalate membranes.
After incubation for 24 h, the cells that did not migrate through the pores in the membrane
were removed by scraping the membrane with a cotton swab. Cells that transversed the
membranes were stained with a Diff-Quick cell staining kit (Dade Behring, Inc., Newark,
DE). Invasion assay of prostate cancer cells was carried out as described above except that
24 well BD BioCoat™ Matrigel™ invasion chambers (8 µm pore size; Becton Dickinson)
were used and the incubation time was 22 h. Cells at three random fields per insert were
counted with 40× magnification and expressed as the average number of cells per field of
view. Three independent experiments were performed in triplicates in each condition. The
data were presented as the mean of three independent experiments ±SD.
3.5 Statistical Analysis
The Student’s t-test was used for analysis of the significance of differences in means
between control and tested samples. P<0.05 was considered significant.
4. Results
3.1 TNF? enhancement of selectin binding to LNCaP cells
LNCaP C-81 cells with and without TNF? treatment were assessed for their binding to P-,
E-, and L-selectins by flow cytometry. These cells exhibited a decreasing order of selectin
binding, P-selectin > L-selectin > E-selectin, in the untreated controls (Figs. 1A–C). TNF?
treatment increased the number of cells that bind to E, P, and L-selectins by 240%
(p<0.001), 12% (p<0.05), and 43% (p<0.05), respectively (Fig. 1A–C).
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3.2 TNF? enhancement of sLex and 6-sulfo-sLex epitopes on LNCaP cells
The E- and L-selectin ligands, sLex and 6-sulfo-sLex, on C-81 LNCaP cells were assessed
with KM93 and G152 antibodies, respectively. As shown in Fig. 2A and 2B, TNF?
treatment increased the binding of LNCaP cells to KM93 and G152 antibodies by 248%
(p<0.001) and 21% (p<0.05), respectively.
3.3 TNF? modulation of the expression of glycosyl- and sulfotransferase genes involved in
the synthesis of selectin ligands
The TNF?-induced changes in the expression of the glycosyl- and sulfotransferase genes
involved in the synthesis of mucin-type selectin ligands were assessed by real time PCR
analysis. As shown in Fig. 3, TNF? treatment of LNCaP cells significantly increased the
expression of the following genes (% increase over the control): C2GnT1 (340%) (p<0.01),
B4GalT1 (68%) (p<0.05), GlcNAc6ST3 (760%) (p<0.01) and ST3Gal3 (240%) (p<0.05).
Although C1GALT1 gene expression was not affected by TNF?, it did express at a high
basal level, i.e. 0.11% of GAPDH. However, the gene expression level of core 1 extension
enzyme, B3GnT3, was very low, i.e. 0.00006% of GAPDH. C2GnT1 is the highest expresser
among the three C2GnT isozymes. All B4GalTs were expressed at very high levels. After
TNF? treatment, GlcNAc6ST1 & 3 were expressed at modest levels, ST3Gal4 was the
highest expresser among the three ST3Gal isozymes and FUT4 was the highest expresser
among the FUT genes.
3.4 TNF? enhancement of in vitro motility and invasion of LNCaP cells
The motility and invasion properties of LNCaP cells treated with TNF? were analyzed by in
vitro Boyden chamber assay. As shown in Fig. 4A–4C, TNF? treatment significantly
increased the number of cells that migrated through polyethylene terapthalate membrane by
83% (p<0.001) and those that invaded the matrigel by 44% (p<0.001) when compared with
the untreated cells. Incubation of the TNF?–treated cells with KM93 antibodies and E-
selectin reduced the number of cells that migrated through polyethylene terapthalate
membrane by 81% (p<0.001) and 52% (p<0.001), respectively, and those that invaded the
matrigel by 45% (p<0.001) and 56% (p<0.001), respectively when compared with the cells
treated with TNF? only.
4. Discussion
Metastasis is the primary cause of cancer death. and inflammation is a key contributor of
cancer metastasis [27, 28]. Current study shows that TNF?, a proinflammatory cytokine,
enhances the motility and invasiveness of human prostate cancer cells by stimulating the
expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of
selectin ligands. These results support the role of inflammation in cancer metastasis [29].
Cancer metastasis involves several highly coordinated steps, including escaping of tumor
cells from the primary sites, transport of these cells by circulation to the lymphoid organs
and/or distant sites, adhesion of these cells to the inflamed endothelium at these sites, and
then establishment of tumors. Interactions of selectins and their ligands play a crucial role in
the second and third steps of the metastatic process as described above. The circulating
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metastatic cancer cells provide sLex, an E-selectin ligand, to facilitate their arrest by the E-
selectin present on the activated endothelium at distant sites [30,31]. The L-selectin ligand,
6-sulfo-sLex, expressed on the surface of these cancer cells help them adhere to the
circulating leukocytes by binding to L-selectin expressed on the surface of leukocytes,
which facilitates their transport to the lymphoid organs and inflamed endothelium at distant
sites. The P-selectin ligand expressed on these cancer cells render these cells capable of
adhering to P-selectin present on the activated endothelium at distant sites and on circulating
platelets, which help these cancer cells to metastasize [30]. The increased expression of P-,
E-, and L-selectin ligands on these cancer cells following treatment with TNF? could
enhance the potential of these cells to target to the lymphoid organs and inflamed
endothelium at distant sites. In this study, we have shown that TNF? enhances the motility
and invasiveness of these prostate cancer cells. Confirmation of this observation in vivo
remains to be made.
SLex and 6-sulfo-sLex can be found on core 1 and core 2 mucin glycans [31,32]. The
formation of these glycotopes is controlled by the levels of these enzymes of which
expression is subject to regulation [31,33]. For example, TNF? has been shown to increase
the production of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa
by stimulating the expression of glycosyl- and sulfotransferases responsible for their
synthesis [18]. The enzymes responsible for the enhancement of these glycotopes have been
shown to be FUT3 & 4, ST3Gal3 & 4, and GlcNAc6STs. TNF? also can enhance the
production of sulfated N-acetyllactosamine, a precursor of 6-sulfo-sLex on CD44 of a SR91
myloid cell line [34]. In this report, we showed increased production of P-, E-, and L-
selectin ligands on LNCaP cells treated with TNF?. Upregulation of C2GnT-1, B4GalT1,
GlcNAc6ST3 and ST3Gal3 genes coupled with high expression levels of additional glycosyl-
and sulfotransferase genes can explain the formation of these selectin ligands in response to
TNF? treatment. However, the low expression level (0.00005% of GAPDH) of the core 1
extension enzyme (B3GnT3) suggests that the core 1 can not be extended to support the
formation of these glycotopes on this core structure. Therefore, these selectin ligands are
most likely localized to the core 2 branch. This prediction remains to be confirmed by
glycan analysis.
We extended the biochemical and molecular biological observations by showing that TNF?-
induced changes in glycogene expression profile led to increased binding of these cells to P-,
E-, and L-selectins, and increased their adhesion, motility, and invasion properties. This
observation confirmed a previous report that TNF? increased migration and invasion of a
human melanoma cell line [35]. Collectively, these results support the idea that
inflammatory cytokines can enhance the metastatic properties of cancer cells and further
substantiate the link between inflammation and cancer progression as previously described
[27, 28].
In conclusion, the present study shows the TNF? effect on enhancement of prostate cancer
cell migration and invasion through activation of selective glycosyl and sulfotransferase
genes involved in the biosynthesis of sialylated and/or sulfated sLex. These genes may serve
potential therapeutic targets.
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Highlights
In this communication, we have made the following observations.
> TNF?, a proinflammatory cytokine, enhances the motility and invasiveness of
prostate cancer cells.
> TNF? enhances the production of selectin ligands in prostate cancer cells, which
results in increased binding to P-, E-, and L-selectins.
> TNF? upregulates the expression of selective glycosyl- and sulfotransferase genes
involved in the synthesis of selectin ligands.
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Fig. 1.
Interactions of selectins and ligands on LNCaP C-81 cells. The decreasing binding order of selectins with C-81 cells were P > L
> E. Treatment of C-81 cells with TNF??(20 ng/ml, 36 h) significantly increased the binding of E-selectin (A), P-selectin (B)
and L-selectin (C) when compared with control cells (*, p<0.05; **, p<0.001).
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Fig. 2.
TNF? enhancement of sLex and 6-sulfo-sLex expression on LNCaP C-81 cells. Treatment of LNCaP cells with TNF?
(20ng/ml, 36 h) significantly increased higher binding of these cells to anti-sLex (A) and 6-sulfo-sLex (B) antibodies (*, p<0.05;
**, p<0.001).
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Fig. 3.
Quantitative RT-PCR analysis of glycosyl- and sulfotransferase gene expression. Quantitative real time PCR analysis was
carried out on LNCaP cells with and without TNF? treatment (20 ng/ml, 3h). Relative expression level of each gene was sorted
according to Ct (see Materials and Methods) calibrated with GAPDH and expressed as % of GAPDH at basal levels and fold
changes determined by calculating the ratio of the expression level of each gene in TNF? treated vs. vehicle-treated cells.
Relative amount of each gene versus that of GAPDH (100%) in untreated control cells was given in the parenthesis (n=3).
Statistical analysis of the difference in means between treated and control cells for each gene was performed by the Student’s t-
test (*, p<0.05; **, p<0.01).
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Fig. 4.
Migration and Invasion of LNCaP cells. LNCaP C-81 cells of 5×104 cells/ml in serum free medium was inoculated in the upper
chambers of 24 well migration and matrigel invasion chamber plates. After 24 h, the cells that transverse to bottom side of the
chamber plates were fixed, stained, and then counted under a phase contrast microscope (40×) in three independent fields for
each insert. The TNF?-treated C-81 cells showed a significantly higher level of migration (A, C) and invasion (B, C) than
control cells through polyethylene terapthalate membrane and matrigel invasion chambers, respectively. Pre-incubation of
TNF? treated cells with sLex specific antibody (KM93) or E-selectin, significantly reduced the number of cells that migrated
(A, C) and invaded (B, C) when compared with cells treated with TNF? alone. The data represented an average of three
independent experiments (*, p<0.001).
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Table 1
Oligonucleotide primers used for quantitative real-time PCR analysis of different glycosyl- and
sulfotransferases
Genes Forward primer sequences 5?-3? Reverse primer sequences 5?-3?
Core 1 AGAAGCAAAGGTCACCAGTCCCAA AGCCAGGATTTAGAGGCCATTTCC
B3GnT3 ATAAGGGAGTGCCAGGGAAGGTTT ACAGTTGGAACTCTAGCACAGGCA
C2GnT1 GCATGGTTTCTGCAGAGCACAGTT TTTCCACAATGCCTTGCTACCTGC
C2GnT2 AGAAGCGAGAGCCTTTCACAGACA TACACAGCTCGCAGTAGCCTTTCA
C2GnT3 GTTCCCTGGGCTTTCCTTGTTTGA ACTCACCTAAGGCCAAAGGGAACA
B4GalT1 CTAGCAACTTGACCTCGGT CATTTGGGTTCTGCTTTGCC
B4GalT2 GCATAACGAACCTAACCCTCAG GCCCAATGTCCACTGTGATA
B4GalT3 GTAACCTCAGTCACCTGCC ATTCCGCTCCACAATCTCTG
B4GalT4 ACTTCGTGGGTGCCATTCAAGAGA AAGGAGACACAGAAGGGCAGTTGT
B4GalT5 TGGAACAGAGTACAGAATGCAG CCTTGCCGTTCTTTTGACTTC
B4GalT6 CTTCACATACTCACCATACCTCC CCCCTGGCTCAATATCTAAATCC
GlcNAc6ST1 CGAAATGGAGCAGTTTGCCCTGAA ACTCCTCCACCTGTTTGATCTGCT
GlcNAc6ST2 ATCCCATGAATTTGCTGGGCTACC AGATGTAGGCAAGGCTCAGAAGCA
GlcNAc6ST3 GCAGACACGCCAAGCTTTGAGAAA AGCTGCAACGCTGATCACAAATCC
GlcNAc6ST4 TAGTGCAACTTCCTGTGAGCCAGT TCCATCAAGCCTCACCTCACAACA
ST3GAL3 TGTTCCTGGATGACTCCTTTCGCA CTTGTTGGCAAGAACGCCTCCATT
ST3GAL4 ATGAGCAGATCACGCTCAAGTCCA TCCCATCTCCAGCATCCGCTTAAT
ST3GAL5 GCACGGATTAGAACTGGG CGCCCTCTGGATAAGTCAT
ST3GAL6 TCTATTGGGTGGCACCTGTGGAAA TGATGAAACCTCAGCAGAGAGGCA
FUT3 AGAGAGATCATCACGGCACGGTTT ATAAGTGGTGGTCCTGGGCTTGAA
FUT4 TGCAGGTGGGACTTTGTTGTTTGG TCCTCCAAGGACAATCCAGCACTT
FUT5 TGCCACACTGAATGTCACCTGCTA TGCTGATGGTCACACACATACCCT
FUT6 ATCACCGCACCGTTTCCAGATGTA TCCCAAAGTGCTGGGATTACAGGT
FUT7 TTCGTGCATGTGGATGACTTTGGC AGCGTTGGTATCGGCTCTCATTCA
FUT9 TCCCATGCAGTTCTGATCCAT CAGCCTCAAGATCATCAGCA
GAPDH TCGACAGTCAGCCGCATCTTCTTT ACCAAATCCGTTGACTCCGACCTT
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